Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 791 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT07016152RecruitingPhase 1
A study of a Klebsiella vaccine for healthy adults
This trial tests a new two-part vaccine (CHO-V08) to prevent Klebsiella pneumoniae infection. It looks at safety and immune response in healthy adults aged 18 to 50.
TaipeiAges 18–50 - NCT07684326RecruitingPhase 2/Phase 3
Can dapagliflozin help liver cirrhosis with fluid buildup? (Phase 2/3 randomized trial)
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
GizaAges 18 years+ - NCT00114647Recruiting
Blood draw to collect plasma or white blood cells for lab tests
This trial uses a special blood-removal procedure called apheresis to collect either plasma or white blood cells for laboratory research. It may help scientists understand infection or immune-related processes by providing specific blood components for study.
Bethesda, MarylandAges 18–100 - NCT07746999Enrolling by invitation
Liver health study for transgender adults
This study looks at liver health in transgender individuals to better understand and improve care. You may join if you are 18 or older and can read and write in English.
Newark, New JerseyAges 18 years+ - NCT06923280Recruiting
Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Beijing, ChinaAges 18–80 - NCT03855917RecruitingPhase 4
Short 4-week hepatitis C treatment for early liver disease
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
Darlinghurst, New South WalesAges 18 years+ - NCT07600788RecruitingPhase 1
Liver Function and Safety Study of AHB-137 Injection
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT07492771RecruitingPhase 1
Study of MP101 for adults with Pseudomonas pneumonia
This trial tests an experimental treatment called MP101 for adults with pneumonia caused by the bacteria Pseudomonas aeruginosa (PA). It aims to help patients whose infection is not responding to current antibiotics.
Seoul, Seodaemun-guAges 19 years+ - NCT04162938Recruiting
Tablet app to help emergency patients learn about hepatitis C
This trial tests whether a patient-friendly electronic app given in the emergency department can increase what you know about hepatitis C and help you move to the next steps of care. It may be most helpful for people who are hepatitis C–positive but don’t yet have clear information about their status.
Baltimore, MarylandAges 18–100 - NCT04713787RecruitingPhase 2
Test higher doses of oxfendazole against single-dose albendazole
This trial studies which dose of oxfendazole works best and is safest for treating a specific intestinal worm infection in adults. It compares different oxfendazole doses to one standard dose of albendazole, and uses stool and blood testing over about 4–6 weeks.
Santa Clara, MaynasAges 18–65 - NCT07663032RecruitingPhase 1
Pan-Salmonella vaccine study for healthy young adults
This trial tests an experimental vaccine designed to protect against multiple types of Salmonella bacteria (which cause typhoid fever and other infections). It is given to healthy adults aged 18 to 45 to check safety and immune response.
BloemfonteinAges 18–45 - NCT05655182RecruitingPhase 1/Phase 2
RSV vaccine study for infants and toddlers who may be at risk
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
La Mesa, CaliforniaAges 6 months–5 years - NCT06825559RecruitingPhase 1
Saroglitazar safety in moderate liver impairment from cholestatic disease
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Indianapolis, IndianaAges 18–80 - NCT07728487RecruitingPhase 1
AT-587 safety study in healthy volunteers
This trial tests a new medication called AT-587 in healthy people to see if it is safe and how the body processes it. You may help by participating if you are in good health and meet the basic requirements.
EdegemAges 18–65 - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT07724496Recruiting
H. pylori and stomach growth features study
This study looks at whether having H. pylori infection (a common stomach bacteria) and certain features of stomach growth can predict how early stomach cancer or pre-cancerous changes will behave and what your long-term outlook might be. You may be eligible if you are being treated with a camera-based removal procedure called endoscopic submucosal dissection (ESD).
Beijing, Beijing MunicipalityAges 18–80 - NCT05457972RecruitingPhase 4
Using vaginal estrogen to support breastfeeding after delivery
This study tests whether using estrogen placed in the vagina after childbirth can help breastfeeding or milk pumping go more smoothly. It’s aimed at people who are at least 6 weeks postpartum and plan to breastfeed or pump.
Cleveland, OhioAges 18–50 - NCT06755632Recruiting
Hepatic fibrosis or cirrhosis screening trial
This trial screens for liver scarring (fibrosis) or severe scarring (cirrhosis) caused by hepatitis B or C. It aims to find people who may benefit from further care or treatment.
BobignyAges 18 years+ - NCT07717437Recruiting
Liver cancer registry for patients who had vein embolization
This registry collects medical images and health information from patients with liver cancer or liver metastases who had a procedure to block certain liver veins (PVE/HVE). The goal is to learn more about this technique and help future patients.
Chicago, IllinoisAges 18 years+ - NCT05960656RecruitingPhase 1
Study of SGLT2 inhibitor effects on liver sugar production
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
San Antonio, TexasAges 30–75 - NCT07053293RecruitingEarly Phase 1
Study on diabetes medication and liver sugar production
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
San Antonio, TexasAges 30–75 - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT07397455RecruitingPhase 1
COVID-19 Omicron Human Challenge Study
This study is a 'human challenge' trial where healthy volunteers who have been vaccinated and have low antibody levels are deliberately exposed to a newer Omicron variant of COVID-19. The goal is to learn how the virus spreads and how to test treatments or vaccines.
LondonAges 18–50
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 791 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.